CGA
GSK icon

Crescent Grove Advisors’s GSK GSK Stock Holding History

Crescent Grove Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,432
Closed -$274K – 280
2021
Q2 		$274K Buy
+5,432
New +$261K 0.03% 210

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Crescent Grove Advisors's GSK Position: Q3 2021 in Review

Crescent Grove Advisors sold out of GSK (GSK) in Q3 2021, closing a stake of 5,432 shares — an estimated $274K sold.

Crescent Grove Advisors first reported a position in GSK in Q2 2021 and held it in 1 quarter. The position peaked at $274K in Q2 2021. 792 funds tracked by Wall St. Rank hold GSK as of Q3 2021.

  • Crescent Grove Advisors reported no remaining GSK position as of Q3 2021 after selling out during the quarter.
  • Crescent Grove Advisors sold 5,432 GSK shares in Q3 2021, an estimated $274K.
  • Crescent Grove Advisors first reported a position in GSK in Q2 2021 and held it in 1 quarter.
  • Crescent Grove Advisors's GSK position peaked at $274K in Q2 2021.
  • 792 funds tracked by Wall St. Rank held GSK as of Q3 2021.

Based on Crescent Grove Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.